278 related articles for article (PubMed ID: 30212291)
21. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Pediatric Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia.
Sarkar RR; Gloude NJ; Schiff D; Murphy JD
J Natl Cancer Inst; 2019 Jul; 111(7):719-726. PubMed ID: 30551196
[TBL] [Abstract][Full Text] [Related]
23. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
24. Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia.
Ma Q; Zhang J; O'Brien E; Martin AL; Agostinho AC
J Comp Eff Res; 2020 Aug; 9(12):849-860. PubMed ID: 32602756
[No Abstract] [Full Text] [Related]
25. Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory large B-cell lymphoma in the United States.
Roth JA; Sullivan SD; Lin VW; Bansal A; Purdum AG; Navale L; Cheng P; Ramsey SD
J Med Econ; 2018 Dec; 21(12):1238-1245. PubMed ID: 30260711
[TBL] [Abstract][Full Text] [Related]
26. Discrete Event Simulation to Incorporate Infusion Wait-Time When Assessing Cost-Effectiveness of a Chimeric-Antigen Receptor T Cell Therapy.
Gye A; Lourenco RA; Goodall S
Value Health; 2024 Apr; 27(4):415-424. PubMed ID: 38301961
[TBL] [Abstract][Full Text] [Related]
27. Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial.
Laetsch TW; Myers GD; Baruchel A; Dietz AC; Pulsipher MA; Bittencourt H; Buechner J; De Moerloose B; Davis KL; Nemecek E; Driscoll T; Mechinaud F; Boissel N; Rives S; Bader P; Peters C; Sabnis HS; Grupp SA; Yanik GA; Hiramatsu H; Stefanski HE; Rasouliyan L; Yi L; Shah S; Zhang J; Harris AC
Lancet Oncol; 2019 Dec; 20(12):1710-1718. PubMed ID: 31606419
[TBL] [Abstract][Full Text] [Related]
28. Cost-utility and value of information analysis of tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma in the Irish healthcare setting.
Carey N; Leahy J; Trela-Larsen L; Mc Cullagh L; Barry M
J Mark Access Health Policy; 2023; 11(1):2166375. PubMed ID: 36684853
[TBL] [Abstract][Full Text] [Related]
29. Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma.
Whittington MD; McQueen RB; Ollendorf DA; Kumar VM; Chapman RH; Tice JA; Pearson SD; Campbell JD
JAMA Netw Open; 2019 Feb; 2(2):e190035. PubMed ID: 30794298
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States.
Simons CL; Malone D; Wang M; Maglinte GA; Inocencio T; Wade SW; Bennison C; Shah B
J Med Econ; 2021; 24(1):421-431. PubMed ID: 33634729
[TBL] [Abstract][Full Text] [Related]
31. Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital's Perspective.
Yang H; Hao Y; Qi CZ; Chai X; Wu EQ
J Manag Care Spec Pharm; 2020 Aug; 26(8):971-980. PubMed ID: 32525730
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness Analysis of Tisagenlecleucel Versus Blinatumomab in Children and Young Adults with Acute Lymphoblastic Leukemia: Partitioned Survival Model to Assess the Impact of an Outcome-Based Payment Arrangement.
Gye A; Goodall S; De Abreu Lourenco R
Pharmacoeconomics; 2023 Feb; 41(2):175-186. PubMed ID: 36266557
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness and budget impact analyses of tisagenlecleucel in adult patients with relapsed or refractory diffuse large B-cell lymphoma from Singapore's private insurance payer's perspective.
Wang XJ; Wang YH; Li SCT; Gkitzia C; Lim ST; Koh LP; Lim FLWI; Hwang WYK
J Med Econ; 2021; 24(1):637-653. PubMed ID: 33904359
[TBL] [Abstract][Full Text] [Related]
34. The Cost-effectiveness of Pixantrone for Third/Fourth-line Treatment of Aggressive Non-Hodgkin's Lymphoma.
Muszbek N; Kadambi A; Lanitis T; Hatswell AJ; Patel D; Wang L; Singer JW; Pettengell R
Clin Ther; 2016 Mar; 38(3):503-15. PubMed ID: 26856929
[TBL] [Abstract][Full Text] [Related]
35. A Systematic Review of Health Technology Assessments of Chimeric Antigen Receptor T-Cell Therapies in Young Compared With Older Patients.
Gye A; Goodall S; De Abreu Lourenco R
Value Health; 2022 Jan; 25(1):47-58. PubMed ID: 35031099
[TBL] [Abstract][Full Text] [Related]
36. Cost and cost-effectiveness of immunotherapy in childhood ALL: A systematic review.
Scoleri-Longo Y; Pechlivanoglou P; Gupta S
EJHaem; 2024 Feb; 5(1):166-177. PubMed ID: 38406535
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of Daratumumab-based Triplet Therapies in Patients With Relapsed or Refractory Multiple Myeloma.
Zhang TT; Wang S; Wan N; Zhang L; Zhang Z; Jiang J
Clin Ther; 2018 Jul; 40(7):1122-1139. PubMed ID: 30006069
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.
Petersohn S; Salles G; Wang M; Wu J; Wade SW; Simons CL; Bennison C; Siddiqi R; Peng W; Kloos I; Castaigne G; Hess G
J Med Econ; 2022; 25(1):730-740. PubMed ID: 35611697
[TBL] [Abstract][Full Text] [Related]
39. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]